<DOC>
	<DOCNO>NCT00019474</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person recover side effect chemotherapy . Combining chemotherapy interferon alfa may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy interferon alfa follow filgrastim treating patient gastrointestinal tract cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Interferon Alfa Followed Filgrastim Treating Patients With Gastrointestinal Tract Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient unresectable locally advance advanced gastrointestinal malignancy treat intravenous hydroxyurea , fluorouracil , interferon alfa , filgrastim ( G-CSF ) . II . Determine toxic effect regimen patient . III . Determine reversal toxic effect regimen patient . OUTLINE : Patients stratify accord site primary disease ( hepatobiliary v gastric v pancreatic ) . Patients receive fluorouracil IV 48 hour hydroxyurea IV 48 hour day 1 , 8 , 22 , 29 . Patients also receive interferon alfa subcutaneously ( SC ) day 1 , 3 , 5 filgrastim ( G-CSF ) SC day 3-6 week 1 , 2 , 4 , 5 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 31-60 patient ( 18-33 hepatobiliary gastric cancer 13-27 pancreatic cancer ) accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm pancreatic , gastric , biliary system , hepatocellular carcinoma beyond scope surgical resection Gastrointestinal tract carcinoid tumor carcinoma small bowel allow Bidimensionally measurable disease Ineligible ECOG 6296 ( gastric cancer ) No brain metastasis , unless completely resect CT scan brain normal PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 3 time normal SGOT le 3 time normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No chronic uncontrolled angina No significant coronary artery disease ( even asymptomatic ) cardiac catheterization thallium stress test , patient history atherosclerotic heart disease No congestive heart failure No arrhythmia Pulmonary : No chronic obstructive pulmonary disease No chronic pulmonary disease , include asthma , chronic bronchitis , emphysema , sarcoid , bronchiectasis Neurologic : No cerebellar disease No seizure disorder Other : HIV negative No active serious underlie infection No AIDS No psychiatric illness No organic mental syndrome No major psychoaffective disorder No poorly control diabetes mellitus No serious underlying illness would preclude study No recent history alcohol drug abuse Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior systemic chemotherapy advance disease Prior fluorouracil gemcitabine radiosensitizer allow No prior chemotherapy Endocrine therapy : No concurrent systemic steroid No concurrent hormonal therapy ( exclude birth control pill ) No concurrent steroid antiemetic chronic treatment Radiotherapy : At least 1 month since prior radiotherapy Surgery : See Disease Characteristics Recovered prior surgery Other : At least 1 week since prior beta blocker No concurrent chronic treatment aspirin , nonsteroidal antiinflammatory drug , antihistamine , antianginal medication , extraordinary antihypertensive regimen , antiarrhythmic ( except cardiac glycoside )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>